Примери за използване на Imiquimod cream на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Imiquimod cream 5% is for external use only.
The use of an occlusive dressing is not recommended with imiquimod cream therapy.
Imiquimod cream is indicated for the topical treatment of.
After this period it is essential that imiquimod cream is removed with mild soap and water.
Imiquimod cream should be applied prior to normal sleeping hours.
You could resume treatment with imiquimod cream after the skin reaction has moderated.
Imiquimod cream should be used with caution in patients with autoimmune conditions(refer to section 4.5).
In immunocompromised patients, repeat treatment with imiquimod cream is not recommended.
Treatment with imiquimod cream can be resumed after the skin reaction has moderated.
No clinical experience exists with the use of imiquimod cream in immunocompromised patients.
Therefore, imiquimod cream should be used with caution in these patients(see section 4.5).
Avoid the concomitant use of Zyclara and any other imiquimod cream in the same treatment area.
Local skin reactions, such as erythema,are probably an extension of the pharmacologic effects of imiquimod cream.
Response of the treated tumour to imiquimod cream should be assessed 12 weeks after the end of treatment.
Reports have been received of localised hypopigmentation and hyperpigmentation following imiquimod cream use.
Animals were administered imiquimod cream three times per week and were irradiated 5 days per week for 40 weeks.
The application frequency andduration of treatment with imiquimod cream is different for each indication.
Interactions with systemic drugs would be limited by the minimal percutaneous absorption of imiquimod cream.
When applied topically, systemic overdosage with imiquimod cream is unlikely due to minimal percutaneous absorption.
Imiquimod cream therapy is not recommended until the skin has healed after any previous drug or surgical treatment.
Rarely, intense local inflammatory reactions including skin weeping orerosion can occur after only a few applications of imiquimod cream.
Animals were administered imiquimod cream three times per week and were irradiated 5 days per week for 40 weeks.
Local skin reactions are common but these reactions generally decrease in intensity during therapy orresolve after cessation of imiquimod cream therapy.
Imiquimod cream therapy is not recommended until the skin has healed after any previous medicinal products or surgical treatment.
Local skin reactions are common but these reactions generally decrease in intensity during therapy orresolve after cessation of imiquimod cream therapy.
Imiquimod cream therapy should not be initiated in tissues where open sores or wounds exist until after the area has healed.
In the pivotal trials with 3 times a week dosing, the most frequently reported adverse drug reactions judgedto be probably or possibly related to imiquimod cream treatment were application site reactions at the wart treatment site(33.7% of imiquimod treated patients).
Imiquimod cream may weaken condoms and diaphragms, therefore concurrent use with imiquimod cream is not recommended.
Topical administration of imiquimod cream resulted in no tumour enhancement at any dose, in comparison with the vehicle cream group.
Imiquimod cream was evaluated in a photocarcinogenicity bioassay in albino hairless mice exposed to simulated solar ultraviolet radiation(UVR).